Please login to the form below

Not currently logged in

Researcher calls for Roche boycott over missing Tamiflu data

Nordic Cochrane Centre's Peter Gøtzsche also wants European governments to sue the pharma company for withholding data

Roche Tamiflu

A leading researcher has called for doctors to boycott the use of Roche's products until the company publishes all available data related to its flu drug Tamiflu (oseltamivir phosphate). 

Peter Gøtzsche, leader of the Nordic Cochrane Centre – part of the Cochrane Collaboration health research body, also called for European governments to sue the company for withholding data concerning the drug's effectiveness, despite concerns from regulators that it had not been shown to reduce complications in people with influenza.

“Roche has withheld data that purports to show that Tamiflu has dramatic effects,” said Gøtzsche. “We all wonder why it is so difficult to get these data from Roche and why Roche has not published them, if it is really true that they show these effects.”

“As far as I can work out, Tamiflu is likely not any better than paracetamol.”

Gøtzsche made his comments in response to an open letter from the British Medical Journal to John Bell, regius professor of medicine at Oxford University and a Roche board member, that claimed the company was keeping evidence of Tamiflu's  effectiveness and safety “hidden” and called for Professor Bell to use his influence to encourage Roche to publish all its data on the drug.

This letter was published alongside an editorial from the BMJ's editor Fiona Godlee announcing that the Journal would only publish clinical trials of drugs for which full data is openly available.

Roche responded to the letter saying it “does not accept or agree” with its content regarding the company's transparency, and that Roche “complies with all legal requirements regarding the publication of data”.

Furthermore, Roche's letter states it had provided the Cochrane group with 3,200 pages of information “enabling their questions to be answered” and that a further request for information was denied because the researchers “declined to sign a confidentiality agreement”.

This is disputed by the Cochrane group, according to the BMJ, with researchers stating they were never offered a confidentiality agreement at the time of the further request.

In addition, the BMJ also challenged Roche's claim in its letter that it had made full data availability to authorities.

“[T]he Cochrane researchers say the European Medicines Agency has confirmed to them that it does not have some modules of the studies,” said the BMJ in a statement.

13th November 2012

From: Research, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...